Voya Investment Management LLC Buys 17,064 Shares of Cencora, Inc. (NYSE:COR)

Voya Investment Management LLC grew its position in Cencora, Inc. (NYSE:COR - Free Report) by 5.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 310,646 shares of the company's stock after purchasing an additional 17,064 shares during the period. Voya Investment Management LLC owned about 0.16% of Cencora worth $69,796,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. JFS Wealth Advisors LLC lifted its stake in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in shares of Cencora during the 4th quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC lifted its position in Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after purchasing an additional 69 shares during the period. Kentucky Trust Co bought a new position in shares of Cencora in the fourth quarter worth about $33,000. Finally, WASHINGTON TRUST Co grew its position in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after acquiring an additional 46 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Cencora Stock Performance

Shares of COR traded up $1.85 during mid-day trading on Monday, hitting $287.75. The stock had a trading volume of 1,334,120 shares, compared to its average volume of 1,522,104. The company has a market cap of $55.80 billion, a PE ratio of 40.93, a PEG ratio of 1.31 and a beta of 0.55. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $296.65. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company's fifty day simple moving average is $268.09 and its two-hundred day simple moving average is $249.54.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.76%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is presently 31.29%.

Insider Activity at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the sale, the chairman now directly owns 315,913 shares of the company's stock, valued at $89,027,442.53. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,223 shares of company stock worth $13,580,967 over the last 90 days. Insiders own 10.80% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Bank of America boosted their target price on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Evercore ISI increased their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Wells Fargo & Company raised their target price on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Morgan Stanley set a $288.00 price target on Cencora in a research report on Tuesday, April 15th. Finally, JPMorgan Chase & Co. raised their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $284.55.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.